US Stock MarketDetailed Quotes

SNSE Sensei Biotherapeutics

Watchlist

0.542
-0.058-9.62%

Trading Nov 26 11:51 ET

13.64MMarket Cap-455P/E (TTM)

Sensei Biotherapeutics Stock Forum

Jaguar8

Oct 21 14:45

Hey 👋

$Sensei Biotherapeutics (SNSE.US)$

Sedliberanosamalo

May 24 09:07

Good news but price down

$Sensei Biotherapeutics (SNSE.US)$ anyone got any insights why? shoed FDA phase 1 approved.

Trytosaveabit

May 23 16:26

Here is the data I was waiting on!

$Sensei Biotherapeutics (SNSE.US)$ Sensei Biotherapeutics Inc: Reported Encouraging Clinical Data From Dose Escalation Portion of Its Phase 1/2 Trial of Sns-101
Once Every 3-Week Dosing of Sns-101 Demonstrates Initial Signs of Promising Clinical Activity
Pharmacokinetic and Safety Profile Validate Conditionally Active Approach in Study
Sensei Biotherapeutics Inc: Expects to Report Initial Data From Dose Expansion Cohorts and to Hold an End-of-Phase 1 Meeting With...

Trytosaveabit

May 14 04:56

Watching for data coming

$Sensei Biotherapeutics (SNSE.US)$ • There have been no dose limiting toxicities (DLT) observed across both the monotherapy and the combination arms.
• Sensei will present topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024.
• Title: Initial result...

Tom2808

May 2 13:04

$Sensei Biotherapeutics (SNSE.US)$ can we push pass 1.9 and go 2 onwards

Stock Region

Apr 5 10:33

Biotherapeutics Company Announces Revolutionary Cancer Treatment Development

Revolutionary Cancer Treatment on the Horizon: How Sensei Biotherapeutics' SNS-101 Could Change the Game.
In the ongoing battle against cancer, groundbreaking research and innovative treatments are the beacons of hope for patients worldwide. One such beacon shines brightly from the laboratories of Sensei Biotherapeutics, Inc., a clinical-stage immuno-oncology company dedicated to the discovery and development of next-gen...

Jaguar8

Apr 4 16:52

$Sensei Biotherapeutics (SNSE.US)$
NEWS
Sensei Biotherapeutics, Inc. (SNSE) announces the publication of a research paper in Nature Communications detailing the development of SNS-101, a pH-sensitive monoclonal antibody targeting VISTA to suppress T-cell activation in cancer patients. The paper highlights the unique mechanism of SNS-101 in mitigating CRS risk and maintaining a favorable safety profile, potentially revolutionizing VISTA-directed immunotherapy.

Newbee4

Mar 25 20:16

Interesting News

$Sensei Biotherapeutics (SNSE.US)$ @Trytosaveabit

Moomoo AI

Nov 1, 2023 06:32

The appointment of Krebs is viewed as a positive step for Sensei, as it may further the company's capabilities in strategic alliances, pipeline expansion and program development. Her extensive experience could be valuable to the company's growth.